Wanhuida Intellectual Property

Wu Xiaohui of Wanhuida Intellectual Property reports on an invalidation decision that demonstrates the importance of patentees limiting and generalising technical features in claims so that they can be sufficiently supported by the specification

Wu Xiaoping of Wanhuida Intellectual Property analyses a decision that carries great weight in differentiating between monopolistic behaviour and the exercise of valid intellectual property rights

Honghui Hu of Wanhuida Intellectual Property explains that a CNIPA ruling on a patent covering an antidepressant could help to determine the patentability of pharmaceutical compounds

Wu Xiaohui of Wanhuida Intellectual Property explains a pioneering case heard by the Intellectual Property Court of the Supreme People’s Court and considers its implications for original and generic drug makers

Jianhui Li of Wanhuida Intellectual Property explains how China addresses the question of whether the features of an administration process limit a patented product and distinguish it from prior art

Yue Guan of Wanhuida Intellectual Property reports on a case in China that has implications for the drafting of compound patents incorporating Markush claims

Feng Zheng and Xiaoyang Yang of Wanhuida outline the various defence mechanisms patentees have at their disposal when facing infringement accusations in China

Tiejun Tang, Yuming Wang, and Jianhui Li of Wanhuida Intellectual Property discuss the evolving landscape in China around ‘offering for sale’, with reference to a high-profile Supreme People’s Court case involving a patented drug

Xiaohui Wu of Wanhuida Intellectual Property reports on a ruling by the Supreme People’s Court of China that emphasises that the determination of common knowledge in the assessment of inventiveness should be incontrovertible

Yue Guan of Wanhuida Intellectual Property analyses a decision by the China National Intellectual Property Administration on the validity of a pulmonary hypertension drug and the implications for pharmaceutical patentees

Jianhui Li and Honghui Hu of Wanhuida Intellectual Property discuss the antitrust scrutiny of China’s Supreme People’s Court in a patent infringement appeal concerning reverse payment settlement agreement

Feng (Janet) Zheng of Wanhuida Intellectual Property provides an insight into obtaining evidence on the infringing product/process and the calculation of damages in China